223 related articles for article (PubMed ID: 19074100)
1. Investigative tools for diagnosis and management.
Munshi NC
Hematology Am Soc Hematol Educ Program; 2008; ():298-305. PubMed ID: 19074100
[TBL] [Abstract][Full Text] [Related]
2. [Updated criteria for diagnosis and risk stratification in patients with multiple myeloma].
Djurdjević P; Andjelković N; Bila J
Srp Arh Celok Lek; 2011 Dec; 139 Suppl 2():95-102. PubMed ID: 22352190
[TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.
Sawyer JR
Cancer Genet; 2011 Jan; 204(1):3-12. PubMed ID: 21356186
[TBL] [Abstract][Full Text] [Related]
4. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
Neben K; Jauch A; Hielscher T; Hillengass J; Lehners N; Seckinger A; Granzow M; Raab MS; Ho AD; Goldschmidt H; Hose D
J Clin Oncol; 2013 Dec; 31(34):4325-32. PubMed ID: 24145347
[TBL] [Abstract][Full Text] [Related]
5. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells.
López-Corral L; Gutiérrez NC; Vidriales MB; Mateos MV; Rasillo A; García-Sanz R; Paiva B; San Miguel JF
Clin Cancer Res; 2011 Apr; 17(7):1692-700. PubMed ID: 21325290
[TBL] [Abstract][Full Text] [Related]
6. MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management.
Rajkumar SV
Hematology Am Soc Hematol Educ Program; 2005; ():340-5. PubMed ID: 16304401
[TBL] [Abstract][Full Text] [Related]
7. Newly diagnosed multiple myeloma patients carrying monoallelic deletion of the whole locus of immunoglobulin heavy chain gene have a better prognosis compared to those with t(4;14) and t(14;16).
Duek A; Trakhtenbrot L; Amariglio N; Benyamini N; Zilbershats I; Ganzel C; Shevetz O; Leiba R; Rozic G; Nagler A; Leiba M
Genes Chromosomes Cancer; 2019 Aug; 58(8):516-520. PubMed ID: 30675954
[TBL] [Abstract][Full Text] [Related]
8. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
[TBL] [Abstract][Full Text] [Related]
9. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.
Dimopoulos M; Kyle R; Fermand JP; Rajkumar SV; San Miguel J; Chanan-Khan A; Ludwig H; Joshua D; Mehta J; Gertz M; Avet-Loiseau H; Beksaç M; Anderson KC; Moreau P; Singhal S; Goldschmidt H; Boccadoro M; Kumar S; Giralt S; Munshi NC; Jagannath S;
Blood; 2011 May; 117(18):4701-5. PubMed ID: 21292778
[TBL] [Abstract][Full Text] [Related]
10. Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the Region of Southern Denmark.
Christensen JH; Abildgaard N; Plesner T; Nibe A; Nielsen O; Sørensen AG; Kerndrup GB;
Cancer Genet Cytogenet; 2007 Apr; 174(2):89-99. PubMed ID: 17452249
[TBL] [Abstract][Full Text] [Related]
11. Myeloma genetics and genomics: practice implications and future directions.
Faiman B
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):436-40. PubMed ID: 25127058
[TBL] [Abstract][Full Text] [Related]
12. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.
Neben K; Jauch A; Bertsch U; Heiss C; Hielscher T; Seckinger A; Mors T; Müller NZ; Hillengass J; Raab MS; Ho AD; Hose D; Goldschmidt H
Haematologica; 2010 Jul; 95(7):1150-7. PubMed ID: 20220069
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors for multiple myeloma in the era of novel therapies.
Ziogas DC; Dimopoulos MA; Kastritis E
Expert Rev Hematol; 2018 Nov; 11(11):863-879. PubMed ID: 30334460
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
[TBL] [Abstract][Full Text] [Related]
15. [Monoclonal gammopathy--multiple myeloma].
Dietzfelbinger H
MMW Fortschr Med; 2005 Jun; 147(24):32-3, 35-6. PubMed ID: 16001531
[TBL] [Abstract][Full Text] [Related]
16. Natural history of multiple myeloma with de novo del(17p).
Lakshman A; Painuly U; Rajkumar SV; Ketterling RP; Kapoor P; Greipp PT; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Dispenzieri A; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
Blood Cancer J; 2019 Mar; 9(3):32. PubMed ID: 30846679
[TBL] [Abstract][Full Text] [Related]
17. Genomic profiling of myeloma: the best approach, a comparison of cytogenetics, FISH and array-CGH of 112 myeloma cases.
Rack K; Vidrequin S; Dargent JL
J Clin Pathol; 2016 Jan; 69(1):82-6. PubMed ID: 26338801
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling.
Stewart AK; Fonseca R
J Clin Oncol; 2005 Sep; 23(26):6339-44. PubMed ID: 16155017
[TBL] [Abstract][Full Text] [Related]
19. Chromosomal defects in multiple myeloma.
Clarke SE; Fuller KA; Erber WN
Blood Rev; 2024 Mar; 64():101168. PubMed ID: 38212176
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal gammopathy and multiple myeloma: incidence of chromosomal aneuploidy detected by interphase fluorescence in situ hybridization.
Cianciulli AM; Coletta AM; Pescatore B; Greco C; Del Monte G; Leonardo C; Venturo I; Gandolfo GM
Eur J Histochem; 1997; 41 Suppl 2():157-8. PubMed ID: 9859828
[No Abstract] [Full Text] [Related]
[Next] [New Search]
